Scientific and corporate news

Company News

Stem Cells from Adipose Tissue

SSCB from this year, thanks also to its GMP (Good Manufacturing Practice) certification, offers a new service to its customers, giving the possibility to store stem cells from adipose tissue for potential future use.

Read More »
Company News

New openings of Zurich and Rome offices

In 2021, SSCB is pleased to announce the opening of new offices in Zurich and Rome, thanks to the achievement of many new milestones, such as the collaboration with the Swiss Stem Cells Foundation (SSCF). 

Read More »
Scientific News

Stem cell secretome from adipose tissue as a biotherapeutic agent to inhibit growth of triple-negative breast cancer 

n this experimental study, a protocol was developed for processing a formulation derived from secretome obtained from adipose tissue mesenchymal stem cells at different concentrations. Its molecular composition and in vitro efficacy was evaluated when applied to breast cancer cell lines. In addition, the ability of the formulation to suppress the growth of triple-negative breast cancer when infused into a mouse model of the disease was verified.

Read More »
Scientific News

Outcomes of adipose tissue stem cell transplantation for the treatment of refractory lupus nephritis

To date, the immunomodulatory capacity of mesenchymal stem cells is well known. In this phase one clinical trial, the efficacy of these cells for the treatment of refractory lupus nephritis (LN) was verified. Specifically, 9 patients received systemic infusion of mesenchymal stem cells derived from adipose tissue and followed up for a 12-month follow-up period.

Read More »
Scientific News

Outcomes of mesenchymal stem cell transplantation from umbilical cord for the treatment of decompensated liver cirrhosis

group (n = 111) and cord blood mesenchymal stem cell infusion group (n = 108). Both groups were followed up for a follow-up period of 7 years (October 2010 to October 2017). Specifically, patients in the control group received only conventional therapy while patients in the other group received three infusions of mesenchymal stem cells from cord tissue at four-week intervals.

Read More »